It has been postulated that oxygen-centered free radicals are produced in significant quantities upon reperfusion of ischemic myocardium and could cause the death of myocytes that are still reversibly injured at the end of ischemia ("reperfusion injury"). However, we have shown previously that anti-free radical therapies including superoxide dismutase (SOD) and inhibitors of xanthine oxidase did not limit infarct size after 40 minutes of ischemia and 4 days of reperfusion in dogs. To test whether 40 minutes of ischemia is too brief a period to produce the prerequisite conditions for free radical-mediated necrosis upon reperfusion, we studied infarcts produced by 90 minutes of ischemia followed by reperfusion. Dogs in an SOD-catalase group received a 60-minute infusion of SOD (i5,000 units/kg) and catalase (55,000 units/kg) beginning 25 minutes before and ending 35 minutes after reperfusion. A second group of dogs received a single injection of the xanthine oxidase inhibitor oxypurinol (20 mg/kg) 25 minutes before reperfusion. Infarct size was assessed histologically relative to the size of the area at risk and to collateral blood flow to the ischemic region. Infarct size as a percentage of the area at risk was similar in the control group (40.7 ± 5.5%, n = 11), the SOD -catalase group (38.0 ± 6.4%; n = 8), and the oxypurinol-treated group (41.4 ± 6.1%; n = 7) [p = not significant (NS) by analysis of variance]. In controls, there was an inverse relation between infarct size and collateral blood flow; neither of the treatments altered this relation (p= NS by analysis of covariance). Thus, neither SODcatalase nor oxypurinol limited infarct size. These results suggest that free radicals, produced by xanthine oxidase and/or accessible to the infused SOD and catalase in the early phase of reperfusion, do not cause substantial myocyte death in this model. From this study and our previous studies, we conclude that differences in the duration of ischemia before reperfusion do not explain the variable results among published studies of therapy directed against free radical production.
It has been well established in experimental studies that timely reperfusion of ischemic myocardium can halt the advancing transmural "wavefront" of ischemic cell death and thereby reduce the amount of necrosis produced by an episode of ischemia. 1 Thus, reperfusion now is a widely used treatment for patients with acute myocardial infarction.2 However, it has been postulated that reperfusion itself may kill some myocytes or endothelial cells that still are reversibly injured at the end of the episode of ischemia. Specific mechanisms through which such "reperfusion injury" could occur include cellular overload of calcium and osmotic cell swelling. However, the most popular hypothesis as to the mechanism of reperfusion injury attributes lethal myocyte or microvascular damage to toxic oxygen metabolites generated during reperfusion. These metabolites include superoxide radical ('02), the hydroxyl radical (-OH), and hydrogen peroxide (H202) . 3 This hypothesis has been supported by direct demonstration with electron spin resonance techniques of increased free radical production during reoxygenation of hypoxic myocardium or reperfusion of ischemic myocardium. [4] [5] [6] Although several different sources of free radicals have been proposed, two important sources during ischemia or reperfusion are thought to be the enzymes xanthine oxidase and reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Xanthine oxidase is involved in the final steps of the ischemia-induced degradation of adenine nucleotides; the reaction forms superoxide anions and hydrogen peroxide.7 8 NADPH oxidase is present in neutrophils, which have been shown to accumulate rapidly in reperfused myocardium. 9, 10 However, although there is now evidence that free radicals are produced during reperfusion, there is a considerable controversy as to whether they cause myocyte death or endothelial injury. Contradictory results have been reported from studies to test whether free radical scavengers such as superoxide dismutase (SOD) and catalase or xanthine oxidase inhibitors such as allopurinol or oxypurinol can limit infarct size after ischemia and reperfusion. Several investigators have reported infarct size limitation by the administration of SOD with or without catalase3,7"11-'6 or by administration of xanthine oxidase inhibitors,7,17-19 but other investigators have been unable to detect a protective effect with similar treatments. [20] [21] [22] [23] [24] [25] [26] Many of these discrepancies may be due to differences in the experimental protocols used. For example, infarct size limitation has been reported from studies of ischemia and reperfusion in which intermediate durations of ischemia (60-90 minutes) have been used.371'1-9 In contrast, in studies of shorter (40 minutes) or longer (3 hours) durations of ischemia, followed by reperfusion, no limitation of infarct size has been detected with allopurinol,20 oxypurinol,24 or SOD. 21, 22 These discrepant results are consistent with the hypothesis that the prerequisite conditions for reperfusion injury are present only transiently (i.e., present with durations of ischemia of more than 40 minutes but disappearing after 3 hours of ischemia).
To test this hypothesis, we studied the effects of a combination of SOD and catalase and of an avid inhibitor of xanthine oxidase, oxypurinol, on the size of infarcts produced by 90 minutes of left circumflex coronary artery occlusion followed by 4 days of reperfusion in dogs. We report that neither of these treatments limited infarct size in this model.
Materials and Methods
In general, experiments were conducted according to the criteria described in the multicenter AMPIM study. 27 The experimental preparation has been described in detail previously.20,22 Briefly, 48 adult mongrel dogs of either sex, weighing 10-25 kg, were anesthetized with sodium pentobarbital and ventilated by a Harvard ventilator (South Natick, Massachusetts) with room air supplemented with low-flow oxygen. A left thoracotomy was per-formed in the fourth intercostal space, and the left circumflex coronary artery was isolated distal to its atrial appendage branch but proximal to its first marginal branch. A piece of umbilical tape was passed around the artery for later occlusion, which was accomplished by snaring the artery into a small plastic tube. Arterial blood gases were maintained within physiological range by adjusting ventilatory parameters as needed. Lead II of the electrocardiogram, arterial and left atrial blood pressures, and pericardial temperature were monitored on a Gould four-channel recorder (Cleveland, Ohio) throughout the experiment. The animals were allowed at least 20 minutes to reach steady state before the first microsphere injection.
Experimental Design Dogs underwent 90 minutes of circumflex coronary artery occlusion followed by reperfusion for 4 days. Regional myocardial blood flow was measured by the microsphere technique27 before ischemia, 10 minutes into occlusion, and 10 minutes before reperfusion. Thirty minutes after occlusion, dogs were randomized into either a control or a treatment group. Animals from the SOD-catalase group received an intra-atrial infusion of a total of 15,000 units/kg body wt bovine liver SOD (approximately 4,500 units/mg protein, suspended with sucrose) (DDI Pharmaceuticals, Mountain View, California) and 55,000 units/kg bovine liver catalase (Sigma Chemical, St. Louis, Missouri). The infusion lasted 1 hour, starting 65 minutes into occlusion (i.e., 25 minutes before reperfusion) and ending 35 minutes after reperfusion. Corresponding controls received an equimolar infusion of Sigma bovine serum albumin (to control for any nonspecific protein effect of SOD or catalase) and sucrose. Animals from the oxypurinol group received 20 mg/kg freshly prepared oxypurinol (Burroughs Wellcome, Research Triangle Park, North Carolina), dissolved into pH 10 saline, as a 2-minute intravenous injection given 25 minutes before reperfusion. Corresponding controls received an equivalent volume of pH 10 saline. Heparinized arterial blood samples were taken for determination of plasma oxypurinol concentration immediately before and 10 minutes after the onset of reperfusion. For determination of plasma SOD concentration, venous blood samples were withdrawn immediately before the initiation of the infusion, 10 minutes before reperfusion (i.e., 15 minutes into the infusion), immediately before reperfusion, and 35 and 60 minutes after reperfusion. Plasma was then separated and frozen for later analysis.
Postmortem Studies
The primary experimental end point was histological infarct size, which was analyzed relative to its major baseline predictors, the area at risk and collateral blood flow. 27 The methods for measuring area at risk and infarct size have been described previously in detail.20,22 Briefly, the anatomic boundaries of the previously ischemic and nonischemic vascular beds were defined by dual perfusion of dyes at physiological pressure in the left main coronary artery and the previously occluded circumflex coronary artery. The perfusate to the circumflex bed contained triphenyl tetrazolium chloride (1%, Sigma) , while that to the nonischemic bed contained Monastral blue dye (0.5%, Du Pont, Wilmington, Delaware). The perfused hearts were fixed in formalin for at least 3 days and then cut into eight transverse sections, which then were photographed. An enlarged projection of each slice was traced, including the boundaries of the ischemic and nonischemic vascular beds; the size of the area at risk was determined by "cut and weigh" techniques. Histological sections that encompassed the entire area at risk were obtained from five of the eight ventricular slices and were stained with the Heidenhain's variant of Mallory's connective tissue stain. Infarct size was determined by tracing enlarged projections of histological sections, followed by cut-and-weigh analysis of the histological tracings. Myocardial blood flow was measured as described previously20,22,27 in the nonischemic and central ischemic zones, the latter consisting of the central 50-60% of the vascular bed at risk. Each region was subdivided into subendocardial, midmyocardial, and subepicardial thirds. Myocardial blood flow was expressed in milliliters per minute per gram. Corrections were made for apparent microsphere loss in dogs that had preocclusion ischemic-nonischemic region flow ratios of less than 0.90.28 Group comparisons of infarct size and hemodynamics were done after excluding five dogs (three control, one SOD-catalase, and one oxypurinol) that did not develop severe subendocardial ischemia (subendocardial blood flow of more than 0.15 ml/min/g).
However, data from all animals were included when comparing infarct size with collateral flow. The effects of SOD-catalase and oxypurinol were unaltered by the addition or exclusion of these dogs with high collateral flow.
Measurement of plasma oxypurinol concentration. Analysis was performed on a Waters Model 840 high-performance liquid chromatography system with a Model 490 detector and a Model 710B sample processor (Milford, Massachusetts). A standard solution of oxypurinol was prepared by spiking a predrug plasma sample with a stock solution to give a 0.1 mM (15.2 ,g/ml) plasma standard. The concentration of the stock solution was adjusted spectrophotometrically. Perchloric acid was added to the samples to precipitate plasma proteins. Analysis was then performed on a Chromanetics 25-cm column with 5 ,m Spherisorb ODS-2 packing (S Con, Winter Park, Florida). The mobile phase was 0.05 M ammonium acetate, pH 6, with 1% acetonitrile. Plasma oxypurinol concentration was deter-the peak area of the plasma and is expressed in micrograms per milliliter.
Measurements of plasma SOD concentrations. Plasma SOD levels were determined with the method of McCord and Fridovich. 29 The assay was performed in 3 ml 0.05 M potassium phosphate buffer, pH 7.8, containing 10`" M EDTA, 10`5 M cytochrome c, and 5 x 0-5 M xanthine. Superoxide anions were then produced by adding sufficient xanthine oxidase to produce a rate of cytochrome c reduction of 0.025 absorbance units/min at 550 nm. The concentration of xanthine oxidase necessary to achieve this rate was variable, but it averaged 10-8 M. One unit of SOD was then defined as the amount of SOD required to reduce the rate of reduction by 50% (i.e., to a rate of 0.0125 absorbance units/min).
Statistical Analysis
Data are expressed as group mean + SEM. Statistical comparisons of group means were made by one-way analysis of variance (ANOVA), followed by a modified unpaired t test if ANOVA was significant. The effects of treatments on hemodynamics or collateral blood flow were analyzed with a paired t test. To control for the variability in infarct size due to collateral flow, infarct size was compared among groups by an analysis of covariance with infarct size as a dependent variable and collateral blood flow as a covariate. p<0.05 was considered statistically significant.
Results
Forty-eight dogs were initially entered into this study; three dogs were excluded because they developed intractable ventricular fibrillation before randomization. Consequently, 45 dogs were randomized: 12 in the SOD-catalase group, 13 in the oxypurinol group, and 20 in the control group. The control group was divided into two subgroups, one receiving albumin and sucrose as a control for SOD-catalase (n = 12) and one receiving pH 10 saline as a control for oxypurinol (n = 8). One animal was excluded from the albumin-sucrose group because of technical difficulties. Three dogs were excluded from the oxypurinol group because of failure to develop myocardial ischemia after coronary occlusion. These animals had transmural mean collateral blood flows of 78%, 94%, and 105% of control flow, respectively (all other dogs had collateral blood flows of less than 40% of preocclusion flow). No necrosis was observed in these three dogs. The two control groups did not show any significant differences in terms of hemodynamics, blood flow, size of the area at risk, or infarct size. Consequently, the two control groups were pooled and are reported as a single group.
The ventricular fibrillation and mortality data are summarized in Table 1 . Three dogs in the control group developed ventricular fibrillation early in the period of reperfusion. Two of the three were defimined by relating the peak area of the standard to brillated successfully; both of these dogs survived 12 1 0 1 10 (83%) Oxypurinol-treated 10 1 0 1 8 (80%) SOD, superoxide dismutase. *Both dogs from the control group that were successfully defibrillated survived to completion of the study.
to completion of the study. Both dogs in the treated groups that developed early reflow ventricular fibrillation (one SOD-catalase and one oxypurinol) could not be defibrillated. Four dogs in the control group died during the first 24 hours of reperfusion. One dog in each treated group died during this period. One of the latter dogs had developed ventricular fibrillation shortly after occlusion and was successfully defibrillated before being randomized into the SOD-catalase-treated group. Overall, there were no significant differences in the incidence of fibrillation or mortality among the different groups.
Myocardial blood flow to the circumflex region is shown in Table 2 and Figure 1 . Preocclusion flows were not significantly different among the groups. All three groups showed markedly reduced transmural mean collateral flow 10 minutes after the occlusion: 0.12 ± 0.03 ml/min/g in controls vs. 0. 14 0.03 in the SOD-catalase-treated and 0.15 ± 0.05 in the oxypurinol-treated dogs. All three groups exhibited a trend to increased collateral blood flow at 80 minutes of occlusion (after treatment) when compared with the 10-minute measurement. However, these differences only reached levels of statistical significance in the control and oxypurinol-treated groups. The same tendency existed in the SOD-catalase-treated group (t= 1.95, p<0. 10). Collateral flows were not significantly different among the three groups at either time.
The intraocclusion hemodynamic data are presented in Table 2 . There were no statistically significant differences in the measured hemodynamic parameters among the three groups.
Plasma levels of SOD were measured in seven dogs and are presented in Figure 2 . After the administration of SOD and catalase, plasma levels of SOD rose from a baseline level of 4.9±+ 0.9 units/ml to 48.8 ± 6.2 units/ml 15 minutes after the onset of infusion and to 78.4 ± 16.8 units/ml at the time of reperfusion. Plasma levels peaked at 100.8 + 15.6 units/ml at the end of the infusion. One hour after reperfusion, plasma levels still were elevated to almost 10 times baseline levels (44.8 ± 3.4 units/ml).
Plasma levels of oxypurinol were measured in eight dogs and averaged 26.6 ± 1.4 ,ug/ml at reperfusion and 21.3±1.0 gg/ml 10 minutes after the onset of reperfusion.
The size of the area at risk, an important baseline predictor of infarct size, was similar in the three groups and averaged 38.8 + 2.0% of the left ventricle in controls, 37.1 +2.0% in the SOD-catalasetreated group, and 40.7 ± 2.1% in the oxypurinoltreated group (Figure 3 and Table 2 ).
Analysis of infarct size, expressed as percentage of the anatomic area at risk, indicated no statistical differences among the groups: 40.7 + 5.5% in controls, 38.0 + 6.4% in the SOD-catalase-treated group, and 41.4 ± 6.1% in the oxypurinol-treated group (Figure 3 , Table 2 ). Thus, by direct group comparison, neither of the treatments was able to limit infarct size. However, it is well known that infarct size, even when expressed relative to the area at risk, is highly variable in dogs. Much of this variation in infarct size is due to variation in collateral blood flow among dogs. 27 To control for this variability, we examined the relation between infarct size and collateral blood flow (Figure 4 ). The 10minute collateral flow measurement was used in the figure because it was made before the onset of any therapy and provides a pretreatment baseline. As observed previously with different durations of ischemia,2022,27 there was a close inverse relation between infarct size and collateral blood flow in controls. Treatment with neither SOD-catalase nor oxypurinol appeared to alter this relation, suggesting that neither of these treatments affected infarct size. This visual observation was confirmed by an analysis of covariance with collateral blood flow as an independent variable and infarct size as a dependent variable (F= 0.154, p = NS). Thus, clearly neither of the treatments limited infarct size, even when the variation due to collateral flow was controlled.
Discussion
In the present study, we showed that treatment with neither SOD-catalase nor oxypurinol limited infarct size when infarcts were caused by 90 minutes of coronary occlusion followed by 4 days of reperfusion in dogs. In previous studies, using a shorter (40 minutes) duration of occlusion, we observed no infarct size limitation with allopurinol,20 oxypurinol,24 or SOD. 22 On the other hand, many investigators using longer (60-90 minutes) durations of ischemia have reported that infarct size was limited by treatment with xanthine oxidase inhibitors or with SOD alone or combined with catalase.3,7,11-19 This diference in results led to the development of the hypothesis that free radical- 100  199  95  200  110  270  113  247  5  11  109  241  5  14   120  320  132  323  102  251  105  241  117  341  120  214  102  263  138  255  130  250  108  255  117  271  4  13  119  272  4  15   110  286  120  225  80  229  100  165  95  262  135  323  90  250  95  315  103  257  6  18  104  249  7  19   222  259  250  158  310  315  199  215  298  279  224  211  216  229  241  12  231  13   310  314  252  232  361  217  270  273  238  257  272  14  273  16   266  253  209  156  216  342  285  319  256  22  247  23  NS NS NS NS Mean + SEM for each group is presented, including all data and after excluding animals without severe subendocardial ischemia (subendocardial blood flow of more than 0.15 ml/min/g). Mean values reported in the text are those calculated without data from these high-flow dogs. No statistical differences were detected whether data from high-flow dogs were included or excluded.
Collateral blood flow was measured at 10 (before drug) and 80 minutes (after drug) into the 90-minute occlusion. LV, left ventricle; AAR, area at risk; IS, infarct size; HR, heart rate (beats/min); SBP, systolic blood pressure (mm Hg); DBP, diastolic blood pressure (mm Hg); RPP, rate pressure product (heart rate x systolic blood pressure/100); SOD, superoxide dismustase. Bar charts of transmural mean collateral blood flow in the control and superoxide dismutase (SOD)-catalaseand oxypurinol-treated groups. Flows were measured at 10 and 80 minutes into the 90-minute occlusion and were not significantly different among the three groups at either of the time points. There was a trend toward increased blood flow between 10 and 80 minutes in all three groups, although this reached statistical significance only in the control and oxypurinoltreated groups. Bars represent mean±SEM.
induced reperfusion injury occurs only after periods of ischemia longer than 40 minutes. This hypothesis is not supported by the results of the present study; no protection was observed with SOD-catalase or oxypurinol with the same duration of occlusion that was used in studies in which infarct size limitation was reported with SOD,3,11,12,14,16 allopurinol,17'18 and oxypurinol. 18, 19 Thus, the discrepancy found in the literature on the effect of SOD or xanthine oxidase inhibitors cannot be explained in terms of differences in the duration of ischemia. This conclusion is reinforced by two other recent studies involving canine models of 90 minutes of ischemia. did not limit infarct size after 24 hours of reperfusion, and preliminary results from Nejima et a125 indicated that SOD-catalase did not limit infarct size after 7 days of reperfusion. There are other potential explanations for these differences in experimental results. First, it is important to consider differences in the way infarct size and its baseline predictors have been measured. In the present study, the extent of necrosis has been assessed by histological techniques, whereas in other studies, infarcts were sized grossly by tetrazolium staining or by visual inspection of the myocardium without histochemical staining. It is possible that, in some cases, tetrazolium staining is not associated with tissue viability, especially when short durations of reperfusion are used. Gross inspection of the myocar- dium without the use of histochemical staining cannot deliver sharp resolution of the borders between necrotic and viable myocardium. In our opinion, histological analysis is the most accurate and reliable way of quantifying infarct size. Second, in the present study, infarct size was related to its major baseline predictors (i.e., area at risk and collateral blood flow). All studies with SOD or xanthine oxidase inhibitors have included measurements of the area at risk. However, most of the studies of dog models from which positive results were reported with SOD3, 11, 14, 16 or xanthine oxidase inhibitors'7,19 did not control for the effect of collateral blood flow. Thus, in some of these studies, the treatment and control groups may not have had equivalent degrees of ischemia. For example, if dogs with higher collateral blood flow were inadvertently assigned to the treatment group, whereas dogs with lower flow were assigned to the control group, a difference in infarct size could occur because of this baseline difference in collateral blood flow.27 In the absence of measurements of collateral flow, such a baseline difference would go undetected and differences in infarct size between groups would be falsely attributed to an effect of treatment. In the study by Puett et al,23 such an analysis showed that oxypurinol treatment had no effect on the relation between infarct size and collateral blood flow. Although every study of the effects of treatment on myocardial ischemia and reperfusion with a dog model should control for variations in collateral blood flow, we also acknowledge that it is quite unlikely that all the published positive results in this field are explained by undetected baseline differences in collateral flow. Also, Ambrosio et al,12 in their study with SOD, examined the relation between infarct size and collateral blood flow. In their study, infarct size limitation with SOD was apparent only in a subset of animals with low collateral blood flow. Such an effect was not found in the study by Puett et a123 and was not found in the present study. Examination of Figure 4 showed that the lack of effect of SOD-catalase or oxypurinol was present both at low and high collateral blood flow levels.
The dosage of the drugs used also needs to be considered. Some investigators administered SOD as a bolus injection at the time of reperfusion to achieve maximal blood levels.7,12 In the present study, like our previous study,22 we chose to give SOD as a 1-hour infusion, extending 35 minutes into the reperfusion period. We reasoned that because of the relatively short half-life of SOD in the bloodstream (reported as 22 minutes by Gallagher et a121), a constant infusion would result in a longer period of time with protective levels of SOD in the blood. A similar protocol has been reported to limit infarct size by Jolly et al. 3 In the present study, plasma levels of SOD after treatment were elevated to 15-20 times the normal plasma levels (Figure 1) . Thus, to an insufficient dosage of the enzyme. After oxypurinol administration, plasma levels of the drug averaged 26.6 ,ug/ml at the onset of reperfusion. It is not known exactly how much oxypurinol is needed to fully inhibit xanthine oxidase in such a model. However, Akizuki et a130 assumed the required level to be around 1 ,ug/ml. In their study, infarct size limitation was reported with an oxypurinol concentration averaging between 1.4 and 5.3 gg/ml. Similarly, Charlat et a131 reported that allopurinol was able to attenuate myocardial stunning when oxypurinol concentration did not exceed 2-3 ,ug/ml. Thus, oxypurinol levels achieved in the present study were well above the concentrations measured in some studies from which positive results were reported.
It is also possible that the technique by which reperfusion was induced could modify the amount of free radicals produced. In the present study, we reperfused abruptly, allowing full reactive hyperemia to develop. In contrast, in some of the positive studies,3"11,16,17'19 reperfusion was performed in the presence of a critical stenosis, which prevents full reactive hyperemia. It is conceivable that such a stenosis might exacerbate reperfusion injury either by limiting the washout of toxic metabolites, such as hypoxanthine and xanthine, or by increasing neutrophil aggregation in the previously ischemic tissue and thereby increasing free radical production.
The duration of reperfusion has also been variable in different studies of the effect of SOD-catalase or xanthine oxidase inhibitors on infarct size. In most cases, infarct size limitation was observed when reperfusion lasted up to 6 hours, 7,11,13-15'17-19 whereas in this and our preceding studies,2022,24 as well as other studies21,23,2526 with reperfusion periods of 1-7 days, no limitation of infarct size was observed. Thus, it is possible that the infarct size limitation with these treatments is temporary, lasting up to 6 hours and disappearing when infarct size is measured after 24 hours or more of reperfusion. There are two possible explanations for such a theoretical effect. First, it is possible that in the presence of a treatment, tetrazolium used early after reperfusion may artifactually stain tissue that is irreversibly injured; this artifact would not be observed when tetrazolium is used after longer periods of reper-fusion21,23,25,26 or when infarct size is assessed histologically.20,22,24 Another possibility is that treatments only delay free radical-induced cell death and that the initially salvaged tissue undergoes necrosis later in the reperfusion phase ("delayed reperfusion injury"). Such a mechanism could occur if free radical production continued after drug levels decreased below their therapeutic levels. For example, free radical production from activated neutrophils could persist well after SOD-catalase have been cleared from the circulation. In this regard, Tamura et al'6 used a polyethylene glycol-conjugated form of SOD characterized by a long half-life (more than 30 hours) and reported positive results with a canine it is unlikely that our negative results could be due model of 90 minutes of ischemia followed by 4 days of reperfusion. Thus, this possibility warrants further investigation. However, this explanation does not account for the marked limitation of infarct size observed with native SOD by Jolly et a13 with a 24-hour reperfusion period or by Ambrosio et a112 with 48 hours of reperfusion.
